Antimicrobial agents against vanco

Resistant enterococci (Linezolid)mycin

Abstract

Oxazolidinones are a new class of antimicrobials with a unique mechanism of action. This class of bacterial protein synthesis inhibitors functions by binding to the 50 S ribosomal subunit and preventing formation of a functional initiation complex in bacterial translation systems.Linezolid (LZD), an oxazolidinone anti-bacterial agent with a mechanism of action distinct from those of conventional antibacterial agents, was recently developed and its effectiveness against methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-insensitive S. aureus (VISA) highly anticipated. LZD has been approved as a new antibiotic against infections with gram-positive organisms by many countries, including the United States. Aclinical trial with LZD against MRSA infection hes been done in Japan.